Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 4, 2009, Pages 513-514

  Becker, Richard C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HUMAN; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK REDUCTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; HEMORRHAGE; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2;

EID: 70350495412     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0385-4     Document Type: Article

References (6)

1. Collet JP, Hulot JS, Pena A et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 373:309-317
2. Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375
3. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354-362
4. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P-450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19):2553-2560
5. CURE Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494-502
6. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001-2015